Raleigh, NC, 10 November 2022 – Catalyst Clinical Research are delighted to have ranked 4th in the Triangle Business Journal’s (TBJ) Fast 50. This is the third consecutive year Catalyst have been awarded this accolade, ranking 40th in 2021 and 9th in 2020 pre-pandemic. This designation recognizes the fastest-growing privately held companies in the Research Triangle region. This ranking represents a return to pre-pandemic levels of growth within the company and highlights our continued drive to offer a people-driven culture.
Senior Vice President of Resourcing Operations, Kathy Bradrick, said TBJs recognition was particularly important as the industry continues to recover from the COVID-19 pandemic which affected the progress of most clinical trials and biopharmaceutical operations.
“It was a great night to celebrate Catalyst and all of the fastest growing companies in the Triangle that are contributing to the success of the local economy. The top 5 winners are all clinical research companies, illustrating the hard work and dedication from our industry during the pandemic.”
Acknowledging the TBJ recognition, Catalyst’s Senior Vice President of Strategy & Solutions, Melissa Church said the Fast 50 ranking is another metric highlighting the company’s consistent growth trajectory over the past 3 years.
“We are thrilled to again be included in the Triangle Business Journal’s Fast 50. Our success is directly attributed to Catalyst’s commitment to our values and creating a culture that enables us all to do our best work.”
Companies eligible for the Fast 50 designation must meet several criteria, including:
- Independent and privately held
- Based and headquartered in one of the 16 counties that comprise the Triangle region: Chatham, Durham, Edgecombe, Franklin, Granville, Harnett, Johnston, Lee, Moore, Nash, Orange, Person, Vance, Wake, Warren and Wilson
- Completed three full years of operation by December 31, 2021 with revenue of at least $10 million in 2021
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology. With over 500 staff and offices in the US and EU, the company provides multi-therapeutic global resourcing and functional services through Catalyst Flex and a full-service oncology CRO offering through Catalyst Oncology. The company’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.